Vacuum therapy may stop deadly leaks after esophageal cancer surgery

NCT ID NCT06097078

Ongoing Disease control Sponsor: Aesculap AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special vacuum device placed inside the esophagus right after cancer surgery to prevent dangerous leaks where the stomach is reconnected to the esophagus. About 44 adults having minimally invasive esophageal cancer surgery will receive this preventive treatment. The goal is to see if it lowers the rate of anastomotic leaks, a serious complication that can lead to infection or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Eso-SPONGE® device (endoluminal vacuum therapy)
What this could lead to: If it works, this could offer a way to prevent a serious complication after esophageal cancer surgery, potentially reducing infections and deaths.
What could go wrong: This is a small, early-stage study with only 44 participants and no comparison group, so results may not apply broadly. The device itself carries risks like discomfort or rare injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANASTOMOTIC LEAK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anastomotic Leak esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANASTOMOTIC LEAK ESOPHAGEAL CANCER ESOPHAGUS CANCER

Contacts and locations

Locations

Hospital Clinic de Barcelona

Barcelona, Catalonia, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.